Research into small amphibians has been stymied by limited means of tracking their movements, hindering conservation efforts. Harmonic direction finding technology, adapted from avalanche rescue ...

DALLAS--(BUSINESS WIRE)--Lantern Pharma (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug ...

-- Multiple chemically distinct, next-generation oral KIT inhibitors in exploratory toxicology studies; on track to nominate development candidate in 2023 CAMBRIDGE, Mass., Dec. 15, 2022 (GLOBE ...

BELTSVILLE, Md., May 3, 2023 /PRNewswire/ -- Reprocell USA, a CRO, has been awarded a contract to provide support for Lantern Pharma's (LTRN) Phase 2 clinical trial entitled "A Study of LP-300 With ...

Ongoing neuroscience research on psychedelic drugs like LSD and psilocybin is increasingly demonstrating the healing potential of these substances. In the case of LSD, researchers note in a recent ...

For the initial safety lead-in portion of the Phase 2 study, which involved 7 patients, all patients received the LP-300 drug candidate with pemetrexed and carboplatin intravenously2. Preliminary ...

-- Multiple chemically distinct, next-generation oral KIT inhibitors in exploratory toxicology studies; on track to nominate development candidate in 2023 The Company is initiating nonclinical studies ...